Nuclear magnetic resonance –based co-magnetometers are essential tools for applications ranging from inertial navigation to geophysical exploration and biomedical sensing. Their performance critically ...
Abstract: In electric traction applications, researchers are employing pole phase modulation (PPM) based multiphase induction machines (MIM) to achieve a broader range of speed and torque, allowing ...
Abstract: The presence of adversarial examples can cause synthetic aperture radar (SAR) image classification systems to produce incorrect predictions, severely compromising their accuracy and ...
Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational ...
NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its Phase 2a ...
Clinical Trials Arena on MSN
Precision gains FDA approval to begin Phase I/II FUNCTION-DMD trial
The trial aims to assess the tolerability, safety, efficacy, functional outcomes, and dystrophin expression in affected patients.
The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division. This was supported by lab experiments showing that lowering deuterium levels ...
The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...
Chowning is a composer, musician and professor that had a seismic impact on both the development of music technology and the ...
LCGC International salutes Jack Henion and Bob W.J. Pirok, winners of the 19th annual LCGC Lifetime Achievement and Emerging ...
Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has been dosed in a Phase 1a/2a clinical trial ...
NMD Pharma is accelerating ignaseclant’s clinical development in CMT alongside multiple near-term clinical catalysts across its neuromuscular pipeline, with Phase 2 studies in spinal muscular atrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results